Candriam S.C.A. Acquires Shares of 114,110 Vaxcyte, Inc. (NASDAQ:PCVX)

Candriam S.C.A. acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 114,110 shares of the company's stock, valued at approximately $9,341,000. Candriam S.C.A. owned about 0.09% of Vaxcyte at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in shares of Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock valued at $1,247,954,000 after acquiring an additional 2,052,989 shares during the period. RA Capital Management L.P. grew its holdings in Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock valued at $992,914,000 after purchasing an additional 485,436 shares during the period. State Street Corp increased its stake in Vaxcyte by 1.1% in the third quarter. State Street Corp now owns 3,405,743 shares of the company's stock valued at $389,174,000 after purchasing an additional 38,596 shares in the last quarter. Franklin Resources Inc. raised its holdings in Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock worth $315,162,000 after purchasing an additional 324,560 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Vaxcyte by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company's stock valued at $308,675,000 after buying an additional 259,010 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Remove Ads

Insider Activity at Vaxcyte

In related news, Director Teri Loxam sold 6,250 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares of the company's stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,250 shares of company stock valued at $4,550,258. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Vaxcyte stock traded up $0.96 during midday trading on Tuesday, reaching $69.85. The stock had a trading volume of 973,145 shares, compared to its average volume of 1,190,000. The stock has a market capitalization of $8.99 billion, a P/E ratio of -15.18 and a beta of 1.02. The firm's fifty day simple moving average is $83.06 and its 200-day simple moving average is $94.66. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent analyst reports. Guggenheim restated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They set a "buy" rating and a $135.00 price target on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and a consensus price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.